RESUMO
No abstract available.
Assuntos
Artérias , Corioide , Angiografia por Ressonância Magnética , VasculiteRESUMO
No abstract available.
Assuntos
Imageamento por Ressonância Magnética , Esclerose Múltipla , NeurossífilisRESUMO
Optic perineuritis (OPN) is a rare form of orbital inflammatory disease of optic nerve sheath. The clinical presentation of OPN are known as distinct from demyelinating optic neuritis (ON). Recently, we have experienced a patient with bilateral idiopathic ON who had initial magnetic resonance imaging (MRI) feature of OPN. Serial MRI and funduscopic examination exhibited the bilateral ON findings. Serial MRI and funduscopic examination are needed in diagnosing OPN to differentiate to the temporal change of ON.
Assuntos
Humanos , Imageamento por Ressonância Magnética , Nervo Óptico , Neurite Óptica , ÓrbitaRESUMO
BACKGROUND: The clinical efficacy and safety of fludarabine combination chemotherapy was investigated for the treatment of previously untreated patients with low-grade (NHL). METHODS: Twenty-five patients who were newly diagnosed as low-grade NHL were treated with fludarabine combination chemotherapy. Fludarabine combination regimens consisted of fludarabine, mitoxantrone and dexamethasone or fludarabine, cyclophosphamide and mitoxantrone with or without rituximab and repeated every 4 weeks. RESULTS: The median age was 60 years (range, 35-77 years), with 13 of 25 patients (52%) > or =60 years of age. Seven of 25 patients (28%) with an intermediate risk follicular lymphoma international prognostic index (FLIPI) and 9 of 25 patients (36%) with a high risk FLIPI were enrolled in this study. The delivered median number of chemotherapy was six (range, 2-9 cycles). The overall response rate with fludarabine-based treatment was 88%, including 52% complete remission and 36% partial remission. During the median follow-up of 19 months, the estimated 2-year event-free survival was 63+/-10% (95% CI, 43-83) and the 2-year overall survival was 78+/-9% (95% CI, 60-96). Fludarabine combination chemotherapy was frequently associated with grade 3 or 4 neutropenia in 84% patients. However, neutropenic infection was observed in only one (4%) patient. Four patients (16%) showed grade 3 or more non-hematologic toxicities, such as acute coronary syndrome, intracranial hemorrhage, anaphylaxis and gastric cancer. CONCLUSION: Fludarabine-combination treatment was a highly active regimen with well toleration in untreated low-grade NHL.
Assuntos
Humanos , Síndrome Coronariana Aguda , Anafilaxia , Anticorpos Monoclonais Murinos , Ciclofosfamida , Dexametasona , Intervalo Livre de Doença , Quimioterapia Combinada , Seguimentos , Hemorragias Intracranianas , Linfoma , Linfoma Folicular , Linfoma não Hodgkin , Mitoxantrona , Neutropenia , Vidarabina , RituximabRESUMO
Arcanobacterium haemolyticum is a catalase-negative, aerobic gram-positive rod. It causes pharyngitis, skin and soft tissue infection, osteomyelitis, endocarditis, meningitis, pneumonia, and septicemia. We experienced a case of A. haemolyticum bacteremia and osteomyelitis in a diabetic patient. The organism was misidentified as Cellulomonas species by automated system but correctly identified as A. haemolyticum by 16s rRNA sequencing.
Assuntos
Humanos , Arcanobacterium , Bacteriemia , Cellulomonas , Endocardite , Meningite , Osteomielite , Faringite , Pneumonia , RNA , Sepse , Análise de Sequência , Pele , Infecções dos Tecidos MolesRESUMO
Drug-eluting stents (DES) are considered the treatment of choice for most patients with obstructive coronary artery disease when percutaneous intervention (PCI) is feasible. However, stent thrombosis seems to occur more frequently with DES and occasionally is associated with resistance to anti-platelet drugs. We have experienced a case of recurrent stent thrombosis in a patient with clopidogrel resistance. A 63-year-old female patient suffered from acute myocardial infarction and underwent successful PCI of the left anterior descending coronary artery (LAD) with two DESs. She was found to be hyporesponsive to clopidogrel and was treated with triple anti-platelet therapy (aspirin 100 mg, clopidogrel 75 mg, and cilostazol 200 mg daily). Three days after discharge, she developed chest pain and was again taken to the cardiac catheterization laboratory, where coronary angiography (CAG) showed total occlusion of the mid-LAD where the stent had been placed. After intravenous administration of a glycoprotein IIb/IIIa inhibitor, balloon angioplasty was performed, resulting in Thrombolysis In Myocardial Infarction (TIMI) III antegrade flow. The next day, however, she complained of severe chest pain, and the electrocardiogram showed marked ST-segment elevation in V1-V6, I, and aVL with complete right bundle branch block. Emergent CAG revealed total occlusion of the proximal LAD due to stent thrombosis. She was successfully treated with balloon angioplasty and was discharged with triple anti-platelet therapy.
Assuntos
Feminino , Humanos , Pessoa de Meia-Idade , Administração Intravenosa , Angioplastia com Balão , Bloqueio de Ramo , Cateterismo Cardíaco , Cateteres Cardíacos , Dor no Peito , Angiografia Coronária , Doença da Artéria Coronariana , Vasos Coronários , Stents Farmacológicos , Eletrocardiografia , Glicoproteínas , Infarto do Miocárdio , Stents , Tetrazóis , Trombose , TiclopidinaRESUMO
Rituximab is a chimeric monoclonal antibody that specifically targets the CD20 molecule on the B cell surface. Although rituximab was originally introduced for the treatment of lymphoid neoplasms such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), it is now emerging as an effective and relatively safe therapeutic option for the patients with refractory immune thrombocytopenic purpura (ITP). We report here on a case of life-threatening toxic epidermal necrolysis (TEN) that was related with the use of rituximab in a patient with refractory ITP. The patient developed extensive erythematous papules and bullous lesions on his whole body associated with fever and visual disturbance during the second cycle of rituximab. The rituximab was discontinued and high dose intravenous immunoglobuline and steroid were administrated. Four weeks later, he fully recovered without any sequelae. A review of the literature reveals this to be the first reported case of TEN associated with rituximab injection in Korea.